Immunogenicity for Biopharmaceuticals & Biosimilars Asia
15th October 2012 — 17th October 2012

Predicting and mitigating the risk of unwanted immunogenicity

Event Overview

Immunogenicity: First event of its kind in Asia

Informa Life Sciences has over a decade-long experience in hosting Immunogenicity conferences in the US and Europe and is pleased to present the inaugural Immunogenicity for Biopharmaceuticals & Biosimilars Asia 2012.  The ONLY event of its kind in the region, researched with and designed for the community of scientists driving progress and innovation in immunogenicity studies in the region. Bringing you global best practices and case studies, teamed with emerging local knowledge, this event will assist you in formulating solutions to your top immunogenicity challenges.

“Governments in Asia like Korea and Singapore, have identified biopharmaceuticals as one of the future engines for economic growth”

- ensure success in the design and commercialization of your biotherapies understanding, predicting and minimizing
the risk of immunogenic responses.

This comprehensive programme will provide you with a detailed insight to the immunogenicity field, including the underlying causes and implications of immunogenicity, current international developments and best practices in immunogenicity risk assessment, prediction, assay development and regulatory expectations and particular considerations for immunogenicity in the Asian region.

Programme Highlights

This comprehensive programme will provide you with a detailed insight to the immunogenicity field, including the underlying causes and implications of immunogenicity, current international developments and best practices in immunogenicity risk assessment, prediction, assay development and regulatory expectations and particular considerations for immunogenicity in the Asian region.

Key discussions across the 2-day programme include:

• Immunogenicity considerations and implications in biosimilar development
• Assessing if there are differences in immunogenic response between the Asian and North European populations and implications in biotherapeutic development
• Successes in reengineering to reduce immunogenicity
• Applying principles learned from immunotherapy to predict and mitigate unwanted immunogenic response

Plus Don’t Miss: Bioanalytical Masterclass

Method Development, Validation and Data Interpretation for Immunogenicity Assays

This masterclass is designed to provide a comprehensive overview for those new to the industry and as a refresher to those familiar with the field. Through means of presentation, discussion and practical exercises, participants will gain a strong foundation in designing and validating immunoassays and interpreting the data generated.

Key speakers this year include:

Dr Jack Ragheb
Chief Medical Research Officer, Laboratory of Immunology
Food & Drug Administration, USA

Dr Shingo Niimi
Division of Biological Chemistry and Biologicals
National Institute of Health Sciences, Japan

Harald Kropshofer, PhD
Senior Personalized Healthcare Leader
F.Hoffmann-La Roche Ltd., Switzerland

Michael G. Tovey Ph.D.
INSERM Director of Research, Laboratory of Biotechnology & Applied Pharmacology
ENS-Cachan, France

Lucia Mori, Ph.D.
Senior Principal Investigator, Singapore Immunology Network (SIgN)
Agency for Science, Technology and Research (A*STAR), Singapore

5 Reasons to Attend Asia Immunogenicity 2012:

• The ONLY event of its kind in Asia - A ‘must attend’ event given the rapid development of the biotech industry in Asia
• The region’s first to market event highlighting strategies for immunogenicity testing and critical advice to predict and manage unwanted immunogenicity
• Immunogenicity is a major bottleneck in the discovery and development of biotherapeutics – Don’t miss this first event in Asia that will provide you with strategies to predict and manage the immunogenicity response
• Bringing together a multidisciplinary audience this event will provide strategies from preclinical through to clinical to understand, predict and minimize the risk of an immunogenic response
• Regulatory guidances for immunogenicity are unclear – Don’t miss your opportunity to hear a regulatory perspective about minimum data requirements for FDA/EU approval

Call for Posters

Share your latest immunogenicity research and findings.
Click here for submission details and deadlines

Suggested Attendees

Senior Scientists, Principal Scientists, Researchers, Directors, Laboratory Heads from biotech and pharma companies

Expected Number of Attendees

MA

View Conference Website: Immunogenicity for Biopharmaceuticals & Biosimilars Asia

Price of Attendance

Please refer to conference website

Brochure

View Event Brochure

Location

Grand Copthorne Waterfront Hotel
392 Havelock Road
Singapore
Singapore
Singapore